Literature DB >> 10971627

Cellular uptake and spread of the cell-permeable peptide penetratin in adult rat brain.

S J Bolton1, D N Jones, J G Darker, D S Eggleston, A J Hunter, F S Walsh.   

Abstract

Investigation of normal and pathological diseases of the central nervous system (CNS) has been hampered by the inability to effectively manipulate protein function in vivo. In order to address this important topic, we have evaluated the ability of penetratin, a novel cell-permeable peptide consisting of a 16-amino acid sequence derived from a Drosophila homeodomain protein, to act as a carrier system to introduce a cargo into brain cells. Fluorescently tagged penetratin was injected directly into rat brain, either into the striatum or the lateral ventricles, and rats were perfusion-fixed 24 h later in order to assess the brain response to the peptide. Immunohistochemistry following intrastriatal injection showed that injection of 10 microg penetratin caused neurotoxic cell death and triggered recruitment of inflammatory cells in a dose-dependent fashion. Doses of 1 microg or less resulted in reduced toxicity and recruitment of inflammatory cells, but interestingly, there was some spread of the penetratin. Injections of an inactive peptide sequence, derived from the same homeodomain, caused little toxicity but could still, however, trigger an inflammatory response. Intraventricular injections showed extensive inflammatory cell recruitment but minimal spread of either peptide. These results suggest that a dose of 1 microg of penetratin peptide is suitable for directing agents to small, discrete areas of the brain and as such is an interesting new system for analysing CNS function.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10971627     DOI: 10.1046/j.1460-9568.2000.00171.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  8 in total

Review 1.  Peptide delivery to the brain via adsorptive-mediated endocytosis: advances with SynB vectors.

Authors:  Guillaume Drin; Christophe Rousselle; Jean-Michel Scherrmann; Anthony R Rees; Jamal Temsamani
Journal:  AAPS PharmSci       Date:  2002

2.  Cellular uptake but low permeation of human calcitonin-derived cell penetrating peptides and Tat(47-57) through well-differentiated epithelial models.

Authors:  Rachel Tréhin; Ulrike Krauss; Annette G Beck-Sickinger; Hans P Merkle; Hanne M Nielsen
Journal:  Pharm Res       Date:  2004-07       Impact factor: 4.200

Review 3.  Inhibition of mitochondrial neural cell death pathways by protein transduction of Bcl-2 family proteins.

Authors:  Lucian Soane; Gary Fiskum
Journal:  J Bioenerg Biomembr       Date:  2005-06       Impact factor: 2.945

Review 4.  The taming of the cell penetrating domain of the HIV Tat: myths and realities.

Authors:  Ashok Chauhan; Akshay Tikoo; Arvinder K Kapur; Mahavir Singh
Journal:  J Control Release       Date:  2006-11-17       Impact factor: 9.776

5.  A cell-penetrating peptide suppresses inflammation by inhibiting NF-κB signaling.

Authors:  Yu Fu Wang; Xiang Xu; Xia Fan; Chun Zhang; Qiang Wei; Xi Wang; Wei Guo; Wei Xing; Jian Yu; Jing-Long Yan; Hua-Ping Liang
Journal:  Mol Ther       Date:  2011-05-10       Impact factor: 11.454

Review 6.  A Historical Review of Brain Drug Delivery.

Authors:  William M Pardridge
Journal:  Pharmaceutics       Date:  2022-06-16       Impact factor: 6.525

7.  Apolipoprotein E-mimetics inhibit neurodegeneration and restore cognitive functions in a transgenic Drosophila model of Alzheimer's disease.

Authors:  Svetlana Sarantseva; Svetlana Timoshenko; Olga Bolshakova; Eugenia Karaseva; Dmitry Rodin; Alexander L Schwarzman; Michael P Vitek
Journal:  PLoS One       Date:  2009-12-07       Impact factor: 3.240

8.  Macropinocytosis activated by oncogenic Dbl enables specific targeted delivery of Tat/pDNA nano-complexes into ovarian cancer cells.

Authors:  Xiuran Niu; Zhihui Gao; Shanshan Qi; Linjia Su; Nan Yang; Xiuli Luan; Jia Li; Qing Zhang; Yingli An; Sihe Zhang
Journal:  Int J Nanomedicine       Date:  2018-08-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.